Sunday, 30 January 2022 16:02

Anticoagulation news items. Weeks commencing 17th and 24th January 2022

Heparin use in acute coronary syndromes and cardiovascular interventions: habit or evidence based?

European Heart Journal
Viewpoint argues certain applications of unfractionated heparin remain guided by historical experience rather than robust clinical trials, and that further studies are required to evaluate indication, dosing, and monitoring required for use in routine cardiovascular procedures.


Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated individuals with haemophilia A or B

Cochrane Database of Systematic Reviews
Review (10 RCTs; n=608) concludes prophylaxis may reduce bleeding frequency and improve joint function, pain and quality of life vs on-demand treatment, even though this does not translate into a detectable improvement of articular damage when assessed by MRI.


Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents

Cochrane Database of Systematic Reviews
This living systematic review (4 RCTs, n=1042) found that the certainty of the available evidence for the comparative effects of aspirin, vitamin K antagonist, low molecular weight heparain, and DOAC on all‐cause mortality, DVT, PE, or bleeding was either low or very low.



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: